

Edgar Filing: CYTOGEN CORP - Form 10-Q

CYTOGEN CORP
Form 10-Q
August 09, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2004

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the transition period from ----- to -----

Commission file number 000-14879

Cytogen Corporation

(Exact Name of Registrant as Specified in Its Charter)

Delaware

22-2322400

(State or Other Jurisdiction of
Incorporation or Organization)

(I.R.S. Employer
Identification Number)

650 College Road East, Suite 3100, Princeton, NJ 08540-5308

(Address of Principal Executive Offices and Zip Code)

Registrant's Telephone Number, Including Area Code: (609) 750-8200

Indicate by check mark whether the registrant: (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days: Yes X No .
--- ---

Indicate by check mark whether the registrant is an accelerated filer
(as defined in Rule 12b-2 of the Exchange Act). Yes X No .
--- ---

Indicate the number of shares outstanding of each of the issuer's
classes of common stock, as of the latest practicable date:

Class

Outstanding at August 1, 2004

Edgar Filing: CYTOGEN CORP - Form 10-Q

Common Stock, \$.01 par value

15,509,293

CYTOGEN CORPORATION

TABLE OF CONTENTS

	Page ----
PART I. FINANCIAL INFORMATION.....	1
Item 1. Consolidated Financial Statements (unaudited).....	1
Consolidated Balance Sheets as of June 30, 2004 and December 31, 2003.....	2
Consolidated Statements of Operations for the Three Months and Six Months Ended June 30, 2004 and 2003.....	3
Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2004 and 2003	4
Notes to Consolidated Financial Statements.....	5
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.....	13
Item 3. Quantitative and Qualitative Disclosures About Market Risk.....	27
Item 4. Controls and Procedures.....	27
PART II. OTHER INFORMATION.....	27
Item 1. Legal Proceedings.....	27
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.....	29
Item 4. Submission of Matters to a Vote of Security Holders.....	29
Item 5. Other Information.....	30
Item 6. Exhibits and Reports on Form 8-K.....	31
SIGNATURES.....	32

PART I - FINANCIAL INFORMATION

ITEM 1 - CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1

CYTOGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(All amounts in thousands, except share and per share data)
(Unaudited)

	JUNE 30, 2004 -----
ASSETS:	
Current assets:	
Cash and cash equivalents	\$ 20,900
Short-term investments	23,940
Accounts receivable, net	1,946
Inventories	1,432
Other current assets	1,130 -----
Total current assets	49,348
Property and equipment, net	747
Quadramet license fee, net	7,372
Other assets	456 -----

Edgar Filing: CYTOGEN CORP - Form 10-Q

\$ 57,923
=====

LIABILITIES AND STOCKHOLDERS' EQUITY:

Current liabilities:

Current portion of long-term liabilities	\$ 58
Accounts payable and accrued liabilities	4,002

Total current liabilities	4,060

Long-term liabilities	2,457

Commitments and Contingencies

Stockholders' equity:

Preferred stock, \$.01 par value, 5,400,000 shares authorized - Series C Junior Participating Preferred Stock, \$.01 par value, 200,000 shares authorized, none issued and outstanding	-
--	---

Common stock, \$.01 par value, 25,000,000 shares authorized, 15,434,211 and 12,857,488 shares issued and outstanding at June 30, 2004 and December 31, 2003, respectively	155
Additional paid-in capital	425,655
Accumulated deficit	(374,404)

Total stockholders' equity	51,406

\$ 57,923
=====

The accompanying notes are an integral part of these statements.

2

CYTOGEN CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (All amounts in thousands, except per share data) (Unaudited)

	THREE MONTHS ENDED JUNE 30,		SIX MONTHS ENDED JUNE 30,	
	2004	2003	2004	2003
	-----	-----	-----	-----
REVENUES:				
Product related:				
Quadramet	\$ 1,616	\$ -	\$ 3,470	\$ -
ProstaScint	2,312	1,599	4,039	3,219
Others	-	98	1	363
	-----	-----	-----	-----
Total product revenues	3,928	1,697	7,510	3,582
Quadramet royalties	-	465	-	914

Edgar Filing: CYTOGEN CORP - Form 10-Q

Total product related revenues	3,928	2,162	7,510	4,496
License and contract	24	164	43	307
Total revenues	3,952	2,326	7,553	4,803
OPERATING EXPENSES:				
Cost of product related revenues	2,396	900	4,795	1,810
Selling, general and administrative	4,914	2,967	8,805	5,366
Research and development	541	718	1,345	1,530
Equity in loss of joint venture	542	1,086	1,351	1,966
Total operating expenses	8,393	5,671	16,296	10,672
Operating loss	(4,441)	(3,345)	(8,743)	(5,869)
INTEREST INCOME	106	23	170	59
INTEREST EXPENSE	(49)	(46)	(93)	(93)
Loss before income taxes	(4,384)	(3,368)	(8,666)	(5,903)
INCOME TAX BENEFIT	-	-	-	(584)
NET LOSS	\$ (4,384)	\$ (3,368)	\$ (8,666)	\$ (5,319)
BASIC AND DILUTED NET LOSS PER SHARE	\$ (0.30)	\$ (0.37)	\$ ((0.63)	\$ (0.60)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING	14,848	9,051	13,859	8,909

The accompanying notes are an integral part of these statements.

3

CYTOGEN CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (All amounts in thousands) (Unaudited)

	SIX MONTHS ENDED JUNE 30,	
	2004	2003
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net loss	\$ (8,666)	\$ (5,319)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	534	306

Edgar Filing: CYTOGEN CORP - Form 10-Q

Stock-based compensation expenses	11	502
Amortization of deferred revenue	-	(192)
Non-cash interest income	28	-
Loss on disposition of assets	3	-
Write down of property and equipment	100	-
Changes in assets and liabilities:		
Receivables, net	(501)	488
Inventories	455	(767)
Other assets	247	(293)
Accounts payable, accrued liabilities and other liabilities	(1,127)	(574)
	-----	-----
Net cash used in operating activities	(8,916)	(5,849)
	-----	-----
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchases of property and equipment	(371)	(2)
Increase in short-term investments	(7,383)	-
	-----	-----
Net cash used in investing activities	(7,754)	(2)
	-----	-----
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from issuance of common stock	24,021	4,739
Payment of long-term liabilities	(81)	(84)
	-----	-----
Net cash provided by financing activities	23,940	4,655
	-----	-----
Net increase (decrease) in cash and cash equivalents	7,270	(1,196)
Cash and cash equivalents, beginning of period	13,630	14,725
	-----	-----
Cash and cash equivalents, end of period	\$ 20,900	\$ 13,529
	=====	=====
Supplemental disclosure of non-cash information:		
Capital leases of equipment.....	\$ 70	\$ -
	=====	=====
Supplemental disclosure of cash information:		
Cash paid for interest.....	\$ 93	\$ 93
	=====	=====

The accompanying notes are an integral part of these statements.

CYTOGEN CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. THE COMPANY

BACKGROUND

Edgar Filing: CYTOGEN CORP - Form 10-Q

Founded in 1980, Cytogen Corporation (the "Company" or "Cytogen") of Princeton, New Jersey is a product-driven, oncology-focused biopharmaceutical company that develops and commercializes a balanced portfolio of oncology products that address the unmet medical needs of patients and the physicians that serve them. The Company directly markets Quadramet(TM) (samarium Sm-153 lexidronam injection), ProstaScint(R) (capromab pendetide) kit for the preparation of Indium In-111 capromab pendetide and NMP22(R) BladderChek(R) (nuclear matrix protein 22) in the United States. The Company has exclusive United States marketing rights to Combidex(R) (ferumoxtran-10), an investigational molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from non-cancerous lymph nodes, which is under review by the U.S. Food and Drug Administration (the "FDA"). The Company is also developing therapeutics targeting prostate-specific membrane antigen ("PSMA"), a protein highly expressed on the surface of prostate cancer cells and the neovasculature of solid tumors.

Cytogen has had a history of operating losses since its inception. The Company currently relies on two products, ProstaScint and Quadramet, for substantially all of its revenues. In addition, the Company has, from time to time, stopped selling certain products, such as OncoScint(R) CR/OV and the BrachySeed(TM) products, that the Company previously expected would generate significant revenues for its business. The Company's products are subject to significant regulatory review by the FDA and other federal and state agencies, which requires significant time and expenditures in seeking, maintaining and expanding product approvals. In addition, the Company relies on collaborative partners to a significant degree to, among other things, manufacture its products, secure raw materials, and provide licensing rights to their proprietary products for the Company to sell and market to others.

BASIS OF CONSOLIDATION

The consolidated financial statements include the financial statements of Cytogen and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

BASIS OF PRESENTATION

The consolidated financial statements and notes thereto of Cytogen are unaudited and include all adjustments, which in the opinion of management, are necessary to present fairly the financial condition and results of operations as of and for the periods set forth in the Consolidated Balance Sheets, Consolidated Statements of Operations and Consolidated Statements of Cash Flows. All such accounting adjustments are of a normal, recurring nature. The consolidated financial statements do not include all of the information and

footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America and should be read in conjunction with the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission, which includes financial statements as of and for the year ended December 31, 2003. The results of the Company's operations for any interim period are not necessarily indicative of the results of the Company's operations for any other interim period or for a full year.

CASH AND CASH EQUIVALENTS

Cash and cash equivalents include cash on hand, cash in banks and all highly-liquid investments with a maturity of three months or less at the time of

Edgar Filing: CYTOGEN CORP - Form 10-Q

purchase.

SHORT-TERM INVESTMENTS

Short-term investments at June 30, 2004 and December 31, 2003 were \$23.9 million and \$16.6 million, respectively, and consisted of investments in U.S. government agency notes. The Company has the ability and intent to hold these investments until maturity. Held-to-maturity investments are recorded at amortized cost, adjusted for the accretion of discounts or premiums. Discounts or premiums are accreted into interest income over the life of the related investment on a straight-line basis. Dividend and interest income are recognized when earned. These investments mature at various times through April 15, 2005.

IMPAIRMENT OF LONG-LIVED ASSETS

In accordance with Statement of Financial Accounting Standards ("SFAS") No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets," if indicators of impairment exist, management assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows and eventual disposition of the asset. If impairment is indicated, management measures the amount of such impairment by comparing the carrying value of the assets to the present value of the expected future cash flows associated with the use of the asset.

During the second quarter of 2004, the Company recorded a non-cash charge of \$100,000 for equipment impairment associated with the planned closure of the facilities at the Company's AxCell BioSciences subsidiary in July 2004 (see Note 7, "Subsequent Event"). This charge is included in selling, general and administrative expenses for the three and six month periods ended June 30, 2004 in the accompanying consolidated statement of operations.

COSTS ASSOCIATED WITH EXIT OR DISPOSAL ACTIVITIES

In accordance with the SFAS No. 146, "Accounting for Costs Associated with Exit or Disposal Activities," the Company is required to record a liability for costs associated with an exit or disposal activity, measured at fair value, in the period in which the liability is incurred. A liability related to one-time termination benefits provided to severed employees as a result of the exit or disposal activity will be recorded when certain criteria have been met and the employees are notified of the details of the plan. A liability for costs

6

to terminate a lease or other contract before the end of its term shall be recognized and measured at its fair value when the Company terminates the contract in accordance with the contract terms. If the contract is an operating lease, the fair value of the liability at the cease-use date shall be determined based on the remaining lease rentals, reduced by estimated sublease rentals that could be reasonably obtained for the property, even if the Company does not intend to enter into a sublease.

In July 2004, as part of our continuing effort to reduce non-strategic expenses, the Company initiated a closure of facilities at the Company's AxCell BioSciences subsidiary, which will be accounted for pursuant to SFAS No. 146 (see Note 7, "Subsequent Event").

INVENTORIES

The Company's inventories are primarily related to ProstaScint. Inventories are stated at the lower of cost or market using the first-in, first-out method and consisted of the following (all amounts in thousands):

Edgar Filing: CYTOGEN CORP - Form 10-Q

	JUNE 30, 2004	DECEMBER 31, 2003
	-----	-----
Raw materials.....	\$ -	\$ 11
Work-in-process.....	1,229	1,089
Finished goods.....	203	787
	-----	-----
	\$ 1,432	\$ 1,887
	=====	=====

NET LOSS PER SHARE

Basic net loss per common share is calculated by dividing net loss by the weighted average common shares outstanding during each period. Diluted net loss per common share is the same as basic net loss per share for each of the three and six month periods ended June 30, 2004 and 2003 because the inclusion of common stock equivalents, which consist of warrants and options to purchase shares of the Company's common stock, would be antidilutive due to the Company's losses.

VARIABLE INTEREST ENTITIES

In December 2003, the Financial Accounting Standards Board ("FASB") issued FASB Interpretation No. 46 (revised December 2003) ("FIN 46R"), "Consolidation of Variable Interest Entities" ("VIEs"), which addresses how a business enterprise should evaluate whether it has a controlling financial interest in an entity through means other than voting rights and accordingly should consolidate the entity. FIN 46R replaced FASB Interpretation No. 46 ("FIN 46") which was issued in January 2003. The Company is required to apply FIN 46R to variable interests in VIEs created after December 31, 2003. For variable interests in VIEs created before January 1, 2004, FIN 46R applied beginning on March 31, 2004. For any VIEs that must be consolidated under FIN 46R that were created before January 1, 2004, the assets, liabilities and noncontrolling interests of the VIE initially are measured at their carrying amounts with any difference between the net amount added to the balance sheet and any previously recognized interest being recognized as the cumulative effect of an accounting change. If determining the carrying amounts is not practicable, fair value at

7

the date FIN 46R first applies may be used to measure the assets, liabilities and noncontrolling interest of the VIE.

In June 1999, Cytogen entered into a joint venture with Progenics Pharmaceuticals Inc. ("Progenics," and collectively with Cytogen, the "Members"), to form the PSMA Development Company LLC (the "Joint Venture"). The Joint Venture is currently developing antibody-based and vaccine immunotherapeutic products utilizing Cytogen's exclusively licensed prostate-specific membrane antigen ("PSMA") technology. The Joint Venture is owned equally by the Members (see Note 2, "Equity Loss in the PSMA Development Company LLC"). Cytogen accounts for the Joint Venture using the equity method of accounting.

The Company believes it is not required to consolidate the Joint Venture under the requirements of FIN 46R.

STOCK-BASED COMPENSATION

The Company follows the intrinsic value method of accounting for stock-based employee compensation in accordance with APB Opinion No. 25, "Accounting for Stock Issued to Employees," and related interpretations. The Company records deferred compensation for option grants to employees for the

Edgar Filing: CYTOGEN CORP - Form 10-Q

amount, if any, by which the market price per share exceeds the exercise price per share at the measurement date, which is generally the grant date.

The Company follows the disclosure provisions of SFAS No. 123, "Accounting for Stock-Based Compensation," as amended by SFAS No. 148, "Accounting for Stock-Based Compensation - Transition and Disclosure." Had compensation cost for options been recognized in the consolidated statements of operations using the fair value method of accounting, the Company's net loss and net loss per share would have been as follows (all amounts in thousands, except per share data):

	THREE MONTHS ENDED JUNE 30,		SIX MONTHS JUNE
	2004	2003	2004
	----	----	----
Net loss, as reported.....	\$ (4,384)	\$ (3,368)	\$ (8,666)
Add: Stock-based employee compensation expense included in reported net loss	-	-	11
Deduct: Total stock-based employee compensation expense determined under fair value-based method for all awards.....	(341)	(361)	(574)
Pro forma net loss.....	\$ (4,725)	\$ (3,729)	\$ (9,229)
	=====	=====	=====
Basic and diluted net loss per share, as reported.....	\$ (0.30)	\$ (0.37)	\$ (0.63)
	=====	=====	=====
Pro forma basic and diluted net loss per share.....	\$ (0.32)	\$ (0.41)	\$ (0.67)
	=====	=====	=====

8

RECLASSIFICATION

Certain amounts in prior years' consolidated financial statements have been reclassified to conform to the current year presentation.

2. EQUITY LOSS IN THE PSMA DEVELOPMENT COMPANY LLC

In June 1999, Cytogen entered into a joint venture with Progenics to form the PSMA Development Company LLC. The Joint Venture is owned equally by Cytogen and Progenics. Cytogen accounts for the Joint Venture using the equity method of accounting. Cytogen has recognized 50% of the Joint Venture's operating results in its consolidated statements of operations. The Joint Venture is expected to continue to incur losses in future years provided an agreement between the Members is reached on research program goals and budgets for periods after 2004 and the Joint Venture's operations are funded. In 2004, the Members each expect to provide \$4.2 million in funding for the development of the PSMA technologies through the Joint Venture. Cytogen has funded \$950,000 as of June 30, 2004 and an additional \$1.0 million in July 2004 of its \$4.2

Edgar Filing: CYTOGEN CORP - Form 10-Q

million commitment. The Members have not committed to fund the Joint Venture beyond December 31, 2004 at this time, except for obligations under existing contractual commitments as of that date.

For the three months ended June 30, 2004 and 2003, Cytogen recognized \$542,000 and \$1.1 million, respectively, of the Joint Venture's losses. For the six months ended June 30, 2004 and 2003, Cytogen recognized \$1.4 million and \$2.0 million, respectively, of the Joint Venture's losses. As of June 30, 2004 and December 31, 2003, the carrying value of Cytogen's investment in the Joint Venture was \$148,000 and \$550,000, respectively, which represents Cytogen's investment to date in the Joint Venture less its cumulative share of losses and is recorded in other assets. Selected financial statement information of the Joint Venture is as follows (all amounts in thousands):

BALANCE SHEET DATA:

	JUNE 30, 2004	DECEMBER 31, 2003
	-----	-----
Cash	\$ 523	\$ 1,173
Prepaid expenses.....	31	-
Accounts receivable from Progenics, a related party.....	-	108
	-----	-----
Total assets.....	\$ 554	\$ 1,281
	=====	=====
Accounts payable to Progenics, a related party.....	\$ 14	\$ -
Other accounts payable and accrued expenses.....	260	199
	-----	-----
Total liabilities.....	274	199
	-----	-----
Capital contributions.....	21,298	19,398
Accumulated deficit.....	(21,018)	(18,316)
	-----	-----
Total stockholders' equity.....	280	1,082
	-----	-----
Total liabilities and stockholders' equity.....	\$ 554	\$ 1,281
	=====	=====

9

INCOME STATEMENT DATA:

	THREE MONTHS ENDED JUNE 30,		SIX MONTHS ENDED JUNE 30,		
	-----	-----	-----	-----	-----
	2004	2003	2004	2003	2002
	-----	-----	-----	-----	-----
Interest income.....	\$ 2	\$ 1	\$ 5	\$ 1	\$ 1

Edgar Filing: CYTOGEN CORP - Form 10-Q

Total expenses.....	1,086	2,173	2,707	3,932
	-----	-----	-----	-----
Net loss.....	\$ (1,084)	\$ (2,172)	\$ (2,702)	\$ (3,931)
	=====	=====	=====	=====

3. BRISTOL-MYERS SQUIBB MEDICAL IMAGING, INC.

As a result of the Company's reacquisition of marketing rights to Quadramet from Berlex Laboratories Inc. ("Berlex") in August 2003, the Company assumed all of Berlex's obligations under a manufacturing and supply agreement with Bristol-Myers Squibb Medical Imaging, Inc. ("BMSMI"). Effective January 1, 2004, the Company entered into a new manufacturing and supply agreement with BMSMI whereby BMSMI manufactures, distributes and provides order processing and customer services for Cytogen relating to Quadramet. Under the terms of the new agreement, Cytogen is obligated to pay at least \$4.2 million annually through 2008, unless terminated by BMSMI or Cytogen on two years prior written notice. This agreement will automatically renew for five successive one-year periods unless terminated by BMSMI or Cytogen on two years prior written notice. During the three and six month periods ended June 30, 2004, Cytogen incurred \$1.0 million and \$2.1 million, respectively, of manufacturing costs for Quadramet, all of which is included in cost of product related revenues. The Company also pays BMSMI a variable amount per month for each order of Quadramet placed to cover the costs of customer service, which is included in selling, general and administrative expenses.

4. LITIGATION AND OTHER RELATED MATTERS

On March 17, 2000, the Company was served with a complaint filed against us in the United States District Court for the District of New Jersey by M. David Goldenberg and Immunomedics, Inc. (collectively "Plaintiffs"). The litigation claims that the Company's ProstaScint product infringes a patent purportedly owned by Goldenberg and licensed to Immunomedics. The patent sought to be enforced in the litigation has now expired; as a result, the claim, even if successful, would not result in an injunction barring the continued sale of ProstaScint or affect any other of the Company's products or technology. The Company believes that ProstaScint did not infringe this patent, and that the patent was invalid and unenforceable. On December 17, 2001, Cytogen filed a motion for summary judgment of non-infringement of the asserted claims of the patent-in-suit. The Plaintiffs opposed that motion and filed their own cross-motion for summary judgment of infringement. On July 3, 2002, the District Court denied both parties' summary judgment motions, with leave to renew those motions after presenting expert testimony and legal argument based upon that testimony. The parties subsequently presented expert testimony and submitted additional briefing. On April 29, 2003, the Company's motion for summary

judgment of non-infringement of all asserted claims was granted, Plaintiffs' motion for summary judgment of infringement was denied and the case was ordered closed. On May 12, 2003, Plaintiffs filed a Notice of Appeal regarding this decision to the U.S. Court of Appeals for the Federal Circuit ("Federal Circuit"), and subsequently filed their opening brief on July 28, 2003. On September 22, 2003, Cytogen filed its responsive brief. On October 23, 2003, Plaintiffs filed their reply brief. The appeal was fully briefed and oral argument was held on March 2, 2004. The Federal Circuit on June 23, 2004 issued a ruling on the appeal in which it affirmed the District Court's claim construction ruling and summary judgment of no literal infringement by the Company. However, the Federal Circuit determined that there was an issue of

Edgar Filing: CYTOGEN CORP - Form 10-Q

material fact as to infringement under the doctrine of equivalents. As a result, it reversed the District Court's grant of summary judgment of no infringement under the doctrine of equivalents and remanded the case to the District Court for further proceedings on this issue. Given the uncertainty associated with litigation, the Company cannot give any assurance that the litigation could not result in a material adverse effect on the Company's financial condition, results of operations or liquidity.

In connection with a recent review of certain of the Company's intellectual property, it was determined that the Company was the recipient, beginning in 1998, of correspondence from legal counsel representing the former employer of Dr. Julius Horoszewicz, the sole inventor on the principal United States patent covering ProstaScint. Such correspondence alleged that the patent rights to Dr. Horoszewicz's discoveries were the property of such former employer and that Dr. Horoszewicz had no right to assign them to the Company. The Company vigorously disputed those allegations, and the Company has no record of the matter having been pursued by such former employer subsequent to August 2000. The Company believes that in view of the marketing of the technology covered by the patent through the sale of ProstaScint by the Company, the Company's right to use the underlying technology in its continuing production and sale of ProstaScint should not be at risk. However, if such claims were reasserted, and if it were to be concluded that Dr. Horoszewicz in fact had no right to assign the patent to the Company, a court could determine that the Company has no right to use the technology covered by the patent or that any royalties paid by or payable by the Company in respect of the use of the patent should have been paid in the past, and should in the future be payable, to Dr. Horoszewicz's former employer in lieu of Dr. Horoszewicz. The amount of any such payments, and the Company's liability for them, is not presently determinable, and the Company cannot give any assurance that an adverse determination could not result in a material expenditure to the Company or have a material adverse effect on the Company's financial condition, results of operations or liquidity.

The Company has certain rights to indemnification against litigation and litigation expenses from the inventor of technology used in ProstaScint, which may be offset against royalty payments on sales of ProstaScint. However, given the uncertainty associated with litigation, the Company may incur material expenditures.

11

5. SALE OF COMMON STOCK

In April 2004, the Company issued and sold through a registered direct offering 2,570,000 shares of its common stock at \$10.10 per share, resulting in net proceeds to the Company of approximately \$24.0 million after the payment of placement agency fees and expenses related to the offering.

6. STOCK INCENTIVE PLANS

At the Company's 2004 Annual Meeting of Stockholders held on June 15, 2004, the stockholders of the Company approved the adoption of the Company's 2004 Stock Incentive Plan (the "2004 Plan") and the Company's 2004 Non-Employee Director Stock Incentive Plan (the "2004 Director Plan" and together with the 2004 Plan, collectively, the "2004 Incentive Plans"). An aggregate of 1,200,000 and 375,000 shares of the Company's common stock have been reserved for issuance upon the exercise of option grants or restricted stock awards (as applicable) under the 2004 Plan and 2004 Director Plan, respectively. The 2004 Plan provides for the grant of incentive stock options, non-qualified stock options or restricted stock to the Company's employees, officers, consultants and advisors. The 2004 Director Plan provides for the grant of non-qualified stock options and shares of the Company's common stock, in certain circumstances, to members of

Edgar Filing: CYTOGEN CORP - Form 10-Q

the Company's Board of Directors who are not employees of the Company. The Company intends to file a registration statement on Form S-8 with the Securities and Exchange Commission to register the shares of the Company's common stock underlying option grants or other awards under the 2004 Incentive Plans. Furthermore, upon approval of the 2004 Incentive Plans by our stockholders, no further option grants or awards were, or will be, made under the Company's existing 1995 Stock Option Plan or 1999 Non-Employee Director Stock Option Plan. Any unissued and unallocated options previously reserved under these plans were released from reserves.

7. SUBSEQUENT EVENT

Planned Closure of AxCell BioSciences Facilities

In July 2004, the Company initiated the closure of the facilities at its AxCell BioSciences subsidiary as part of the Company's continuing efforts to reduce non-strategic expenses. As a result of the closure, the Company will record additional charges in the third quarter of 2004 related to employee severance costs and the potential charge for future rental payments on leased facilities that will no longer be used in operations. Research projects through academic, governmental and corporate collaborators will continue to be supported and additional applications for the intellectual property and technology at AxCell are being pursued.

12

ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements regarding future events and our future results are based on current expectations, estimates, forecasts, and projections and the beliefs and assumptions of our management including, without limitation, our expectations regarding results of operations, selling, general and administrative expenses, research and development expenses and the sufficiency of our cash for future operations. Forward-looking statements may be identified by the use of forward-looking terminology such as "may," "will," "expect," "estimate," "anticipate," "continue," or similar terms, variations of such terms or the negative of those terms. These forward-looking statements include statements regarding our intent to hold our investments until maturity, additional funding of the PSMA technologies, potential charges resulting from the closure of AxCell Biosciences, growth and market penetration for Quadramet and ProstaScint, revenues, if any, from NMP22 BladderChek and from our joint venture with Progenics Pharmaceuticals Inc., increased expenses resulting from our sales force and marketing expansion, including sales and marketing expenses for Quadramet, the sufficiency of our capital resources, our need for additional capital and other statements included in this Quarterly Report on Form 10-Q that are not historical facts. Such forward-looking statements involve a number of risks and uncertainties and investors are cautioned not to put any undue reliance on any forward-looking statement. We cannot guarantee that we will actually achieve the plans, intentions or expectations disclosed in any such forward-looking statements. Factors that could cause actual results to differ materially, include, market acceptance of our products, the results of our clinical trials, our ability to hire and retain employees, economic and market conditions generally, our receipt of requisite regulatory approvals for our products and product candidates, the continued cooperation of our marketing and other collaborative and strategic partners, our ability to protect our

Edgar Filing: CYTOGEN CORP - Form 10-Q

intellectual property, and the other risks identified in our Annual Report on Form 10-K for the year ended December 31, 2003 under the caption "Additional Factors That May Affect Future Results" and those under the caption "Risk Factors," as included in certain of our other filings, from time to time, with the Securities and Exchange Commission.

Any forward-looking statements made by us do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. We do not assume, and specifically disclaim, any obligation to update any forward-looking statements, and these statements represent our current outlook only as of the date given.

The following discussion and analysis should be read in conjunction with the consolidated financial statements and related notes thereto contained elsewhere herein, as well as in our Annual Report on Form 10-K for the year ended December 31, 2003 and from time to time in our other filings with the Securities and Exchange Commission.

OVERVIEW

Founded in 1980, Cytogen Corporation of Princeton, New Jersey is a product-driven, oncology-focused biopharmaceutical company that develops and commercializes a balanced portfolio of oncology products that address the unmet

13

medical needs of patients and the physicians that serve them. We directly market Quadramet(TM) (samarium Sm-153 lexitronam injection), ProstaScint(R) (capromab pendetide) kit for the preparation of Indium In-111 capromab pendetide and NMP22(R) BladderChek(R) (nuclear matrix protein 22) in the United States. We have exclusive United States marketing rights to Combidex(R) (ferumoxtran-10), an investigational molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from non-cancerous lymph nodes, which is under review by the U.S. Food and Drug Administration. We are also developing therapeutics targeting prostate-specific membrane antigen (PSMA), a protein highly expressed on the surface of prostate cancer cells and the neovasculature of solid tumors. Full prescribing information for our products is available at www.cytogen.com or by calling 1-800-833-3533. ProstaScint(R) and OncoScint(R) are registered United States trademarks of Cytogen Corporation. We are the owner of a pending United States trademark application, Serial No. 78374967, relating to Quadramet. All other trade names, trademarks or servicemarks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners, and not the property of Cytogen Corporation or any of our subsidiaries.

SIGNIFICANT EVENTS IN 2004

ADDITION TO SENIOR MANAGEMENT

In April 2004, Thomas S. Lytle joined the Company as Senior Vice President of Sales and Marketing. Mr. Lytle has over 25 years of experience in the pharmaceutical industry and has held senior level positions at Amgen, Inc., Pfizer and Lederle Laboratories. At Cytogen, Mr. Lytle is responsible for overseeing strategic sales and marketing initiatives for our existing and future oncology products.

CAPITAL RAISING

In April 2004, we issued and sold 2,570,000 shares of our common stock for \$10.10 per share through a registered direct offering resulting in net proceeds of approximately \$24.0 million after the payment of placement agency

Edgar Filing: CYTOGEN CORP - Form 10-Q

fees and expenses related to the offering. The shares in this transaction were registered under our existing shelf registration statement on Form S-3, which was declared effective by the Securities and Exchange Commission on October 30, 2003.

PATENT INFRINGEMENT LITIGATION UPDATE

In June 2004, we announced a ruling by the U.S. Court of Appeals for the Federal Circuit regarding the recent decision of the U.S. District Court for the District of New Jersey in a patent infringement suit filed by Immunomedics, Inc. The U.S. Court of Appeals for the Federal Circuit determined that the district court correctly construed the claims and, under that construction, our ProstaScint product was not an "intracellular marker substance," and affirmed the district court's grant of summary judgment of no literal infringement. Regarding infringement under the doctrine of equivalents, however, the U.S. Court of Appeals for the Federal Circuit disagreed with the district court's conclusion that there is no issue of material fact and reversed the district court's grant of summary judgment on this point and remanded for further proceedings on the issue.

14

ADVANCED MAGNETICS SUBMITS RESPONSE TO APPROVABLE LETTER FOR COMBIDEX

In June 2004, Advanced Magnetix, Inc. and Cytogen announced that Advanced Magnetix submitted a response to the approvable letter received from the U.S. Food and Drug Administration for Combix, Advanced Magnetix' investigational molecular imaging agent to aid in the non-invasive diagnosis of metastatic lymph nodes that Cytogen will market upon receipt of all appropriate regulatory approvals. In response to the submission, the FDA requested that Advanced Magnetix provide certain additional details underlying the existing supporting data submitted. The FDA subsequently communicated that the data Advanced Magnetix is in the process of gathering, look encouraging to provide a complete response to the approvable letter.

PLANNED CLOSURE OF AXCELL BIOSCIENCES FACILITIES

In July 2004, as part of our continuing efforts to reduce non-strategic expenses, we initiated the closure of facilities at our AxCell BioSciences subsidiary. As a result of the closure, we will record additional charges in the third quarter 2004 related to employee severance costs and the potential charge for future rental payments on leased facilities that will no longer be used in operations. Research projects through academic, governmental and corporate collaborators will continue to be supported and additional applications for the intellectual property and technology at AxCell are being pursued.

RESULTS OF OPERATIONS

THREE MONTHS ENDED JUNE 30, 2004 AND 2003

REVENUES

		INCREASE/ (DECREASE)	
2004	2003	\$	%
----	----	-----	-----
(ALL AMOUNTS IN THOUSANDS, EXCEPT PERCENTAGE DATA)			

Quadramet

Edgar Filing: CYTOGEN CORP - Form 10-Q

Product Sales (commenced August 2003).....	\$ 1,616	\$ -	\$ 1,616	n/a
Royalties (ceased July 2003).....	-	465	(465)	(100)%
ProstaScint.....	2,312	1,599	713	45%
NMP22 BladderChek.....	-	98	(98)	(100)%
License and Contract.....	24	164	(140)	(85)%
	-----	-----	-----	
	\$ 3,952	\$ 2,326	\$ 1,626	70%
	=====	=====	=====	

Total revenues for the second quarter of 2004 were \$4.0 million compared to \$2.3 million for the same period in 2003. Product related revenues, which include product sales and royalties in 2003, accounted for 99% and 93% of total revenues for the second quarters of 2004 and 2003, respectively. License and contract revenues accounted for the remainder of revenues.

QUADRAMET. Cytogen recorded Quadramet sales of \$1.6 million for the second quarter of 2004 compared to \$465,000 of Quadramet royalty revenue during the second quarter of 2003. Quadramet sales and royalties accounted for 41% and 22% of product related revenues for the second quarters of 2004 and 2003,

15

respectively. Berlex Laboratories marketed Quadramet in the United States through July 31, 2003. On August 1, 2003, we reacquired marketing rights to Quadramet from Berlex and began marketing Quadramet through our internal specialty sales force. Effective upon the reacquisition of such marketing rights, we no longer receive royalty revenue from Berlex for Quadramet and we pay royalties to Berlex on our sales of Quadramet. On August 1, 2003, we began recognizing product revenue from our sales of Quadramet. Currently, we market Quadramet only in the United States and have no rights to market Quadramet in Europe. We believe that the future growth and market penetration of Quadramet is dependent upon, among other things: (i) new clinical data supporting the expanded and earlier use of Quadramet in various cancers; (ii) novel research supporting combination uses with other therapies, such as chemotherapeutics and bisphosphonates; and (iii) establishing the use of Quadramet at higher doses to target and treat primary bone cancers. We cannot provide any assurance that we will be able to successfully market Quadramet or that Quadramet will achieve greater market penetration on a timely basis or result in significant revenues for us.

PROSTASCINT. ProstaScint sales were \$2.3 million for the second quarter of 2004, an increase of \$713,000 from \$1.6 million in the second quarter of 2003. Sales of ProstaScint accounted for 59% and 74% of product related revenues for the second quarters of 2004 and 2003, respectively. We believe that such increase in ProstaScint sales is due to a combination of factors. First, we believe that customer demand for ProstaScint has increased due to our focused marketing programs and a higher ProstaScint reimbursement value established for 2004 compared to 2003 that appropriately accounts for the cost of the ProstaScint kit, requisite radioisotope, and compounding costs. Furthermore, we identified new distribution channels to better accommodate customer needs. Finally, for the first time in several years, we implemented price increases for both ProstaScint and Quadramet in late June 2004, while limiting the quantities of ProstaScint that could be purchased by distributors at the pre-increase price. ProstaScint has historically been a challenging product for physicians and technologists to use, in part due to inherent limitations in nuclear medicine imaging. We believe that future growth and market penetration of ProstaScint is dependent upon, among other things, the implementation and continued research relating to advances in imaging technology, new product applications and the validation of PSMA as an independent prognostic indicator. We cannot provide any assurance that we will be able to successfully market

Edgar Filing: CYTOGEN CORP - Form 10-Q

ProstaScint, or that ProstaScint will achieve greater market penetration on a timely basis or result in significant revenues for us.

NMP22 BLADDERCHEK. There were no sales of NMP22 BladderChek during the second quarter of 2004 compared to \$98,000 in the second quarter of 2003. We began promoting NMP22 BladderChek to both urologists and oncologists in the United States in November 2002 using our internal sales force. On October 30, 2003, we entered into an amended and restated distribution agreement with Matritech whereby, effective November 8, 2003, we had the right to non-exclusively market NMP22 BladderChek to urologists through December 31, 2003 and have the right to exclusively market NMP22 BladderChek to oncologists through December 31, 2004. We do not expect that sales of NMP22 BladderChek will result in significant revenues for us.

LICENSE AND CONTRACT REVENUES. License and contract revenues were \$24,000 and \$164,000 for the second quarters of 2004 and 2003, respectively. Under SAB 101, which we adopted in 2000, license revenues from certain up-front, non-refundable license fees previously recognized were deferred and were being amortized over the estimated performance period. During the second quarter of

16

2003, we recognized \$96,000 of previously deferred license revenue. The deferred revenue was fully recognized as of December 31, 2003. During the second quarter of 2004, we recognized \$15,000 of contract revenues compared to \$53,000 in the second quarter of 2003 for limited research and development services provided by us to the PSMA Development Company LLC, our joint venture with Progenics Pharmaceuticals Inc. We expect that the level of future revenues for the remainder of 2004, if any, for contract services provided to the joint venture may vary and will depend upon the extent of research and development services required by the joint venture.

OPERATING EXPENSES

	2004	2003	INCREASE/ (DECREASE)	
	----	----	\$	%
	(ALL AMOUNTS IN THOUSANDS, EXCEPT PERCENTAGE DATA)			
Cost of product related revenues.....	\$ 2,396	\$ 900	\$ 1,496	166%
Selling, general and administrative.....	4,914	2,967	1,947	66%
Research and development.....	541	718	(177)	(25)%
Equity in loss of joint venture.....	542	1,086	(544)	(50)%
	-----	-----	-----	
	\$ 8,393	\$ 5,671	\$ 2,722	48%
	=====	=====	=====	

Total operating expenses for the second quarter of 2004 were \$8.4 million compared to \$5.7 million in the same quarter of 2003.

COST OF PRODUCT RELATED REVENUES. Cost of product related revenues for the second quarter of 2004 were \$2.4 million compared to \$900,000 in the same period of 2003. The increase from the prior year period is due primarily to our assumption, in August 2003, of the responsibility for manufacturing costs for Quadramet including contractual increases in 2004 related to our new agreement with Bristol Myers Squibb Medical Imaging, royalties to Berlex on our sales of Quadramet and the amortization of the up-front payment to Berlex to reacquire Quadramet.

Edgar Filing: CYTOGEN CORP - Form 10-Q

SELLING, GENERAL AND ADMINISTRATIVE. Selling, general and administrative expenses for the second quarter of 2004 were \$4.9 million compared to \$3.0 million in the same period of 2003. The increase from the prior year period is due primarily to the expansion of our sales force and the implementation of other marketing initiatives for our existing products, including Quadramet, which we reacquired from Berlex in August 2003. As of August 1, 2004, we employed 38 people in sales and marketing. The employees in sales and marketing included 8 Clinical Oncology Specialists and 22 Regional and Territory Managers. By comparison, we had 31 employees in sales and marketing as of December 31, 2003. We anticipate that expenditure levels will continue to increase as we continue this expansion.

RESEARCH AND DEVELOPMENT. Research and development expenses for the second quarter of 2004 were \$541,000 compared to \$718,000 in the same period of 2003. The current year expenses reflect the reduction in certain research activities at AxCell, which were partially offset by our increased product development efforts in support of new and expanded uses for Quadramet and ProstaScint. During the second quarter of 2004 and 2003, we incurred \$167,000 and \$357,000, respectively, in expenses relating to AxCell's operations.

17

EQUITY IN LOSS OF JOINT VENTURE. Our share of the loss of the PSMA Development Company LLC, our joint venture with Progenics, was \$542,000 and \$1.1 million during the second quarters of 2004 and 2003, respectively. Such amounts represented 50% of the joint venture's operating losses. We may incur significant and increasing costs in the future to fund our share of the development costs from the joint venture, although we cannot provide any assurance that any further agreements between us and Progenics will be reached regarding the joint venture.

INTEREST INCOME/EXPENSE. Interest income for the second quarter of 2004 was \$106,000 compared to \$23,000 in the same period of 2003. The increase in 2004 from the prior year period was due to higher average cash balances in 2004. Interest expense for the second quarter of 2004 was \$49,000 compared to \$46,000 in the same period of 2003. Interest expense includes interest on outstanding debt and finance charges related to various equipment leases that are accounted for as capital leases.

NET LOSS. Net loss for the second quarter of 2004 was \$4.4 million compared to \$3.4 million reported in the second quarter of 2003. The basic and diluted net loss per share for the second quarter of 2004 was \$0.30 based on 14.8 million weighted average common shares outstanding, compared to a basic and diluted net loss per share of \$0.37 based on 9.1 million weighted average common shares outstanding for the same period in 2003.

SIX MONTHS ENDED JUNE 30, 2004 AND 2003

REVENUES

	2004	2003	INCREASE/ (DECREASE)
	----	----	-----
			\$
(ALL AMOUNTS IN THOUSANDS, EXCEPT PERCENTAGE)			
Quadramet			
Product Sales (commenced August 2003).....	\$ 3,470	\$ -	\$ 3,470
Royalties (ceased July 2003).....	-	914	(914)

Edgar Filing: CYTOGEN CORP - Form 10-Q

ProstaScint.....	4,039	3,219	820
NMP22 BladderChek.....	1	123	(122)
BrachySeed (ceased January 2003).....	-	240	(240)
License and Contract.....	43	307	(264)
	-----	-----	-----
	\$ 7,553	\$ 4,803	\$ 2,750
	=====	=====	=====

Total revenues for the first half of 2004 were \$7.6 million compared to \$4.8 million for the same period in 2003. Product related revenues, which include product sales and royalties, accounted for 99% and 94% of total revenues for the first half of 2004 and 2003, respectively. License and contract revenues accounted for the remainder of revenues.

QUADRAMET. Cytogen recorded Quadramet sales of \$3.5 million for the first half of 2004 compared to \$914,000 of Quadramet royalty revenue during the first half of 2003. Quadramet sales and royalties accounted for 46% and 20% of product related revenues for such periods, respectively. Berlex Laboratories marketed Quadramet in the United States through July 31, 2003. On August 1, 2003, we reacquired marketing rights to Quadramet from Berlex and began marketing Quadramet through our internal specialty sales force. Effective upon

18

the reacquisition of such marketing rights, we no longer receive royalty revenue from Berlex for Quadramet and we pay royalties to Berlex on our sales of Quadramet. On August 1, 2003, we began recognizing product revenue from our sales of Quadramet. Currently, we market Quadramet only in the United States and have no rights to market Quadramet in Europe. We believe that the future growth and market penetration of Quadramet is dependent upon, among other things: (i) new clinical data supporting the expanded and earlier use of Quadramet in various cancers; (ii) novel research supporting combination uses with other therapies, such as chemotherapeutics and bisphosphonates; and (iii) establishing the use of Quadramet at higher doses to target and treat primary bone cancers. We cannot provide any assurance that we will be able to successfully market Quadramet or that Quadramet will achieve greater market penetration on a timely basis or result in significant revenues for us.

PROSTASCINT. ProstaScint sales were \$4.0 million for the first half of 2004, an increase of \$820,000 from \$3.2 million in the first half of 2003. Sales of ProstaScint accounted for 54% and 72% of product related revenues for such periods, respectively. We believe that such increase in ProstaScint sales is due to a combination of factors. First, we believe that customer demand for ProstaScint has increased due to our focused marketing programs and a higher ProstaScint reimbursement value established for 2004 compared to 2003 that appropriately accounts for the cost of the ProstaScint kit, requisite radioisotope, and compounding costs. Furthermore, we identified new distribution channels to better accommodate customer needs. Finally, for the first time in several years, we implemented price increases for both ProstaScint and Quadramet in late June 2004, while limiting the quantities of ProstaScint that could be purchased by distributors at the pre-increase price. ProstaScint has historically been a challenging product for physicians and technologists to use, in part due to inherent limitations in nuclear medicine imaging. We believe that future growth and market penetration of ProstaScint is dependent upon, among other things, the implementation and continued research relating to advances in imaging technology, new product applications and the validation of PSMA as an independent prognostic indicator. We cannot provide any assurance that we will be able to successfully market ProstaScint, or that ProstaScint will achieve greater market penetration on a timely basis or result in significant revenues for us.

Edgar Filing: CYTOGEN CORP - Form 10-Q

NMP22 BLADDERCHEK. NMP22 BladderChek sales during the first half of 2004 were \$1,000 compared to \$123,000 in the same period in 2003. We began promoting NMP22 BladderChek to both urologists and oncologists in the United States in November 2002 using our internal sales force. On October 30, 2003, we entered into an amended and restated distribution agreement with Matritech whereby, effective November 8, 2003, we had the right to non-exclusively market NMP22 BladderChek to urologists through December 31, 2003 and have the right to exclusively market NMP22 BladderChek to oncologists through December 31, 2004. We do not expect that sales of NMP22 BladderChek will result in significant revenues for us.

BRACHYSEED. There were no BrachySeed sales during the first half of 2004 compared to \$240,000 during the first half of 2003, which represented 5% of product related revenues. Effective January 24, 2003, we stopped accepting and filling new orders for the BrachySeed products.

LICENSE AND CONTRACT REVENUES. License and contract revenues were \$43,000 and \$307,000 for the first half of 2004 and 2003, respectively. Under SAB 101, which we adopted in 2000, license revenues from certain up-front,

19

non-refundable license fees previously recognized were deferred and were being amortized over the estimated performance period. During the first half of 2003, we recognized \$193,000 of previously deferred license revenue. The deferred revenue was fully recognized as of December 31, 2003. During the first half of 2004, we recognized \$28,000 of contract revenues compared to \$100,000 in the first half of 2003 for limited research and development services provided by us to the PSMA Development Company LLC, our joint venture with Progenics Pharmaceuticals Inc. We expect that the level of future revenues for the remainder of 2004, if any, for contract services provided to the joint venture may vary and will depend upon the extent of research and development services required by the joint venture.

OPERATING EXPENSES

	2004	2003	INCREASE/ (DECREASE)	
			\$	PERCENTAGE
	(ALL AMOUNTS IN THOUSANDS, EXCEPT PERCENTAGE DOLLARS)			
Cost of product related revenues.....	\$ 4,795	\$ 1,810	\$ 2,985	165%
Selling, general and administrative.....	8,805	5,366	3,439	64%
Research and development.....	1,345	1,530	(185)	(12%)
Equity in loss of joint venture.....	1,351	1,966	(615)	(31%)
	-----	-----	-----	
	\$ 16,296	\$ 10,672	\$ 5,624	52%
	=====	=====	=====	

Total operating expenses for the first half of 2004 were \$16.3 million compared to \$10.7 million in the same period of 2003.

COST OF PRODUCT RELATED REVENUES. Cost of product related revenues for the first half of 2004 were \$4.8 million compared to \$1.8 million in the same period of 2003. The increase from the prior year period is due primarily to our assumption, in August 2003, of the responsibility for manufacturing costs for

Edgar Filing: CYTOGEN CORP - Form 10-Q

Quadramet including contractual increases in 2004 related to our new agreement with Bristol Myers Squibb Medical Imaging, royalties to Berlex on our sales of Quadramet and the amortization of the up-front payment to Berlex to reacquire Quadramet. The increase is partially offset by lower costs associated with our discontinuation of BrachySeed products in January 2003.

SELLING, GENERAL AND ADMINISTRATIVE. Selling, general and administrative expenses for the first half of 2004 were \$8.8 million compared to \$5.4 million in the same period of 2003. The increase from the prior year period is due primarily to the expansion of our sales force and the implementation of other marketing initiatives for our existing products, including Quadramet, which we reacquired from Berlex in August 2003. As of August 1, 2004, we employed 38 people in sales and marketing. The employees in sales and marketing included 8 Clinical Oncology Specialists and 22 Regional and Territory Managers. By comparison, we had 31 employees in sales and marketing as of December 31, 2003. We anticipate that expenditure levels will continue to increase as we continue this expansion.

RESEARCH AND DEVELOPMENT. Research and development expenses for the first half of 2004 were \$1.3 million compared to \$1.5 million in the same period of 2003. The current year expenses reflect the reduction in certain research activities at AxCell, which were partially offset by our increased product development efforts in support of new and expanded uses for Quadramet and

20

ProstaScint. During the first half of 2004 and 2003, we incurred \$418,000 and \$807,000, respectively, in expenses relating to AxCell's operations.

EQUITY IN LOSS OF JOINT VENTURE. Our share of the loss of the PSMA Development Company LLC, our joint venture with Progenics, was \$1.4 million during the first half of 2004 compared to \$2.0 million in the same period of 2003 and represented 50% of the joint venture's operating losses. We may incur significant and increasing costs in the future to fund our share of the development costs from the joint venture, although we cannot provide any assurance that any further agreements between us and Progenics will be reached regarding the joint venture.

INTEREST INCOME/EXPENSE. Interest income for the first half of 2004 was \$170,000 compared to \$59,000 in the same period of 2003. The increase in 2004 from the prior year period was due to higher average cash balances in 2004. Interest expense was \$93,000 for each of the first halves of 2004 and 2003. Interest expense includes interest on outstanding debt and finance charges related to various equipment leases that are accounted for as capital leases.

INCOME TAX BENEFIT. During the first half of 2003, we sold a portion of our New Jersey state net operating losses and research and development credit carryforwards, which resulted in the recognition of \$584,000 in income tax benefit. No such sales occurred in the first half of 2004. Assuming the State of New Jersey continues to fund this program, which is uncertain, the future amount of net operating losses and research and development credit carryforwards which we may sell will also depend upon the allocation among qualifying companies of an annual pool established by the State of New Jersey.

NET LOSS. Net loss for the first half of 2004 was \$8.7 million compared to \$5.3 million reported in the first half of 2003. The basic and diluted net loss per share for the first half of 2004 was \$0.63 based on 13.9 million weighted average common shares outstanding, compared to a basic and diluted net loss per share of \$0.60 based on 8.9 million weighted average common shares outstanding for the same period in 2003.

COMMITMENTS

We have entered into various contractual obligations and commercial commitments. The following table summarizes our contractual obligations as of June 30, 2004 (all amounts in thousands):

	LESS THAN 1 YEAR	1 TO 3 YEARS	4 TO 5 YEARS	MORE 5 YEARS
	-----	-----	-----	-----
Long-term debt(1)	\$ -	\$ 2,280	\$ -	\$ -
Capital lease obligations.....	58	39	16	
Facility leases.....	567	849	113	
Other.....	10	16	1	
Manufacturing and research and development contracts(2)	4,494	4,447	200	7
Investor relations and consulting services.....	492	-	-	
Capital contribution to joint venture(3)	3,250	-	-	
Minimum royalty payments(4).....	1,314	2,000	2,000	4,3
	-----	-----	-----	-----
Total.....	\$10,185	\$ 9,631	\$ 2,330	\$ 5,0
	=====	=====	=====	=====

(1) In August 1998, we received \$2.0 million from Elan Corporation, plc in exchange for a convertible promissory note. The note is convertible into shares of our common stock at \$28 per share, subject to adjustments, and matures in August 2005. The note bears annual interest of 7%, compounded semi-annually, however, such interest was not payable in cash but was added to the principal through August 2000; thereafter, interest is payable in cash. The note contains certain non-financial covenants, with which we were in compliance as of June 30, 2004.

(2) As a result of the August 2003 reacquisition of marketing rights to Quadramet, we assumed all of Berlex's obligations under a manufacturing and supply agreement with BMSMI, including an obligation to pay manufacturing costs. Effective January 1, 2004, we entered into a new manufacturing and supply agreement with BMSMI whereby BMSMI manufactures, distributes and provides order processing and customer services for us relating to Quadramet. Under the terms of the new agreement, we are obligated to pay at least \$4.2 million annually through 2008, unless terminated by BMSMI or us on a two year prior written notice. This agreement will automatically renew for five successive one-year periods unless terminated by BMSMI or us on a two-year prior written notice. Accordingly, we have not included commitments beyond June 30, 2006.

(3) In 2004, each of Cytogen and Progenics expects to provide \$4.2 million in funding for the development of the PSMA technologies through our joint venture with Progenics. Cytogen has funded \$950,000 as of June 30, 2004 and an additional \$1.0 million in July 2004 of its \$4.2 million commitment. Cytogen and Progenics have not yet committed to fund the joint venture beyond December 31, 2004 at this time, except for obligations under existing contractual commitments as of that date.

Edgar Filing: CYTOGEN CORP - Form 10-Q

We may incur significant and increasing costs in the future to fund our share of the development costs from the joint venture, although we cannot be sure that any further agreements between us and Progenics will be reached regarding the joint venture.

- (4) We acquired an exclusive license from The Dow Chemical Company for Quadramet for the treatment of osteoblastic bone metastases in certain territories. The agreement requires us to pay Dow royalties based on a percentage of net sales of Quadramet, or a guaranteed contractual minimum payment, whichever is greater, and future payments upon achievement of certain milestones. Future annual minimum royalties due to Dow are \$1.0 million per year in 2004 through 2012 and \$833,000 in 2013.

22

In addition to the above, we are obligated to make certain royalty payments based on sales of the related product and certain milestone payments if our collaborative partners achieve specific development milestones or commercial milestones.

LIQUIDITY AND CAPITAL RESOURCES

CONDENSED STATEMENT OF CASH FLOWS:

	2004

	(ALL AMOUNTS IN THOUSANDS)
Net loss.....	\$ (8,666)
Adjustment to reconcile net loss to net cash used in operating activities.....	(250)

Net cash used in operating activities.....	(8,916)
Net cash used in investing activities.....	(7,754)
Net cash provided by financing activities.....	23,940

Net increase in cash and cash equivalents.....	\$ 7,270
	=====

OVERVIEW

Our cash and cash equivalents were \$20.9 million as of June 30, 2004, compared to \$13.6 million as of December 31, 2003. The increase in cash and cash equivalents from the December 31, 2003 balance was primarily due to our receipt of net proceeds of approximately \$24.0 million from a registered direct offering of our common stock in April 2004, offset by increased operating expenditures in 2004, including costs to manufacture, promote and support our existing oncology products and to expand our internal sales force. During the first half of 2004 and 2003, net cash used for operating activities was \$8.9 million and \$5.8 million, respectively. In 2004, we expect operating expenditures to increase over 2003 levels.

As of June 30, 2004, our total cash, cash equivalents and short-term investments were \$44.8 million compared to \$30.2 million as of December 31, 2003.

Historically, our primary sources of cash have been proceeds from the issuance and sale of our stock through public offerings and private placements, product related revenues, revenues from contract research services, fees paid under license agreements and interest earned on cash and short-term investments.

Our financial objectives are to meet our capital and operating requirements through revenues from existing products and licensing arrangements.

Edgar Filing: CYTOGEN CORP - Form 10-Q

To achieve these objectives, we may enter into research and development partnerships and acquire, in-license and develop other technologies, products or services. Certain of these strategies may require payments by us in either cash or stock in addition to the costs associated with developing and marketing a product or technology. However, we believe that, if successful, such strategies may increase long-term revenues. There can be no assurance as to the success of such strategies or that resulting funds will be sufficient to meet cash requirements until product revenues are sufficient to cover operating expenses, if ever. To fund these strategic and operating activities, we may sell equity or debt securities as market conditions permit or enter into credit facilities.

23

We have incurred negative cash flows from operations since our inception, and have expended, and expect to continue to expend in the future, substantial funds to implement our planned product development efforts, including acquisition of products and complementary technologies, research and development, clinical studies and regulatory activities, and to further our marketing and sales programs. We expect that our existing capital resources should be adequate to fund our operations and commitments into 2007. We cannot assure you that our business or operations will not change in a manner that would consume available resources more rapidly than anticipated. We expect that we will have additional requirements for debt or equity capital, irrespective of whether and when we reach profitability, for further product development costs, product and technology acquisition costs, and working capital.

Our future capital requirements and the adequacy of available funds will depend on numerous factors, including: (i) the successful commercialization of our products; (ii) the costs associated with the acquisition of complementary products and technologies; (iii) progress in our product development efforts and the magnitude and scope of such efforts; (iv) progress with clinical trials; (v) progress with regulatory affairs activities; (vi) the cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights; (vii) competing technological and market developments; and (viii) the expansion of strategic alliances for the sales, marketing, manufacturing and distribution of our products. To the extent that the currently available funds and revenues are insufficient to meet current or planned operating requirements, we will be required to obtain additional funds through equity or debt financing, strategic alliances with corporate partners and others, or through other sources. There can be no assurance that the financial sources described above will be available when needed or at terms commercially acceptable to us. If adequate funds are not available, we may be required to delay, further scale back or eliminate certain aspects of our operations or attempt to obtain funds through arrangements with collaborative partners or others that may require us to relinquish rights to certain of our technologies, product candidates, products or potential markets. If adequate funds are not available, our business, financial condition and results of operations will be materially and adversely affected.

2004 CAPITAL RAISING

In April 2004, we sold 2,570,000 shares of our common stock to certain institutional investors for \$10.10 per share through a registered direct offering, resulting in net proceeds of approximately \$24.0 million after the payment of placement agency fees and expenses related to the offering.

OTHER LIQUIDITY EVENTS

In 2003, we reacquired the marketing rights to Quadramet from Berlex. Accordingly, effective August 1, 2003, we began recording all revenue from sales

Edgar Filing: CYTOGEN CORP - Form 10-Q

of Quadramet. Effective upon the reacquisition of such marketing rights, we no longer receive royalty revenue from Berlex and pay Berlex royalties on our sales of Quadramet. As a result of the reacquisition, we assumed all of Berlex's obligations under a manufacturing and supply agreement with BMSMI. Effective January 1, 2004, we entered into a new manufacturing and supply agreement with BMSMI whereby BMSMI manufactures, distributes and provides order processing and

24

customer services for us relating to Quadramet. Under the terms of the new agreement, we are obligated to pay at least \$4.2 million annually through 2008, unless terminated by BMSMI or us on two years prior written notice. For the first half of 2004, we incurred \$2.1 million of manufacturing costs for Quadramet. This agreement will automatically renew for five successive one-year periods unless terminated by BMSMI or us on a two year prior written notice. We also pay BMSMI a variable amount per month for each Quadramet order placed to cover the costs of customer service. In addition, we expect our Quadramet sales and marketing expenses to increase in 2004.

Beginning in December 2001, we began to equally share the costs of the joint venture with Progenics. Cytogen and Progenics each expect to provide funding of \$4.2 million in 2004. Cytogen has funded \$950,000 as of June 30, 2004 and an additional \$1.0 million in July 2004 of its \$4.2 million commitment. Cytogen and Progenics have not committed to fund the joint venture beyond December 31, 2004 at this time, except for obligations under existing contractual commitments as of that date. We may incur significant and increasing costs in the future to fund our share of the development costs from the joint venture although we cannot provide any assurance that any further agreements between us and Progenics will be reached regarding the joint venture. Any funding amount in subsequent periods may vary dependent upon, among other things, the results of the clinical trials and research and development activities, competitive and technological developments, and market opportunities.

We acquired an exclusive license from The Dow Chemical Company for Quadramet for the treatment of osteoblastic bone metastases in certain territories. The agreement requires us to pay Dow royalties based on a percentage of net sales of Quadramet, or a guaranteed contractual minimum payment, whichever is greater, and future payments upon achievement of certain milestones. Future annual minimum royalties due to Dow are \$1.0 million per year in 2004 through 2012 and \$833,000 in 2013.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Financial Reporting Release No. 60 requires all companies to include a discussion of critical accounting policies or methods used in the preparation of financial statements. Note 1 to our Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2003 includes a summary of our significant accounting policies and methods used in the preparation of our Consolidated Financial Statements. The following is a brief discussion of the more significant accounting policies and methods used by us. The preparation of our Consolidated Financial Statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Our actual results could differ materially from those estimates.

REVENUE RECOGNITION

Product related revenues include product sales by Cytogen to its

Edgar Filing: CYTOGEN CORP - Form 10-Q

customers and Quadramet royalties. Product sales are recognized when the customer takes ownership and assumes risk of loss, and when the collection of the relevant receivable is probable, persuasive evidence of an agreement exists

25

and the sales price is fixed and determinable. Product sales are recorded net of discounts, rebates and estimated allowances for product returns based on our historical experience and any specific product return issues that we may have identified.

Prior to the reacquisition of marketing rights to Quadramet from our marketing partner, Berlex Laboratories, in August 2003, we recognized royalty revenue on Quadramet sales made by Berlex during each period as Berlex sold the product. As a result of our reacquisition, effective August 1, 2003, we began recognizing revenue from the sales of Quadramet and no longer receive Quadramet royalty revenue.

License and contract revenues include milestone payments and fees under collaborative agreements with third parties, revenues from research services, and revenues from other miscellaneous sources.

In 2003, Staff Accounting Bulletin No. 104, "Revenue Recognition" replaced Staff Accounting Bulletin No. 101, "Revenue Recognition In Financial Statements," which the Company adopted in 2000. The provisions related to non-refundable, up-front license fees were unchanged in SAB 104 compared to SAB 101. Accordingly, we defer non-refundable, up-front license fees and recognize them over the estimated performance period of the related agreement, when we have continuing involvement. Since the term of performance periods is subject to management's estimates, future revenues to be recognized could be affected by changes in such estimates.

ACCOUNTS RECEIVABLE

Our accounts receivable balances are net of an estimated allowance for uncollectible accounts. We continuously monitor collections and payments from our customers and maintain an allowance for uncollectible accounts based upon our historical experience and any specific customer collection issues that we have identified. While we believe our reserve estimate to be appropriate, we may find it necessary to adjust our allowance for uncollectible accounts if the future bad debt expense exceeds our estimated reserve. We are subject to concentration risks as a limited number of our customers provide a high percent of total revenues, and corresponding receivables.

INVENTORIES

Inventories are stated at the lower of cost or market, as determined using the first-in, first-out method, which most closely reflects the physical flow of our inventories. Our products and raw materials are subject to expiration dating. We regularly review quantities on hand to determine the need for reserves for excess and obsolete inventories based primarily on our estimated forecast of product sales. Our estimate of future product demand may prove to be inaccurate, in which case we may have understated or overstated our reserve for excess and obsolete inventories.

CARRYING VALUE OF FIXED AND INTANGIBLE ASSETS

Our fixed assets and certain of our acquired rights to market our products have been recorded at cost and are being amortized on a straight-line basis over the estimated useful life of those assets. If indicators of

impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the assets to the present value of the expected future cash flows associated with the use of the asset. Adverse changes regarding future cash flows to be received from long-lived assets could indicate that an impairment exists, and would require the write down of the carrying value of the impaired asset at that time.

ITEM 3 - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We do not have operations subject to risks of foreign currency fluctuations, nor do we use derivative financial instruments in our operations or investment portfolio. As of June 30, 2004, we had \$2.3 million of debt outstanding with a fixed interest rate of 7%. We do not have exposure to market risks associated with changes in interest rates, as we have no variable interest rate debt outstanding. However, downward changes in interest rates could expose us to market risk associated with our fixed interest rate debt.

ITEM 4 - CONTROLS AND PROCEDURES

(a) Evaluation of disclosure controls and procedures. Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of June 30, 2004. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applied its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our chief executive officer and chief financial officer concluded that, as of June 30, 2004, our disclosure controls and procedures were (1) designed to ensure that material information relating to us, including our consolidated subsidiaries, is made known to our chief executive officer and chief financial officer by others within those entities, particularly during the period in which this report was being prepared and (2) effective, in that they provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms.

(b) Changes in internal controls. No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended June 30, 2004 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

On March 17, 2000, we were served with a complaint filed against us in the United States District Court for the District of New Jersey by M. David Goldenberg and Immunomedics, Inc. (collectively "Plaintiffs"). The litigation claims that our ProstaScint product infringes a patent purportedly owned by

Edgar Filing: CYTOGEN CORP - Form 10-Q

Goldenberg and licensed to Immunomedics. The patent sought to be enforced in the litigation has now expired; as a result, the claim, even if successful, would not result in an injunction barring the continued sale of ProstaScint or affect any other of our products or technology. We believe that ProstaScint did not infringe this patent, and that the patent was invalid and unenforceable. On December 17, 2001, we filed a motion for summary judgment of non-infringement of the asserted claims of the patent-in-suit. The Plaintiffs opposed that motion and filed their own cross-motion for summary judgment of infringement. On July 3, 2002, the District Court denied both parties' summary judgment motions, with leave to renew those motions after presenting expert testimony and legal argument based upon that testimony. The parties subsequently presented expert testimony and submitted additional briefing. On April 29, 2003, our motion for summary judgment of non-infringement of all asserted claims was granted, Plaintiffs' motion for summary judgment of infringement was denied and the case was ordered closed. On May 12, 2003, Plaintiffs filed a Notice of Appeal regarding this decision to the U.S. Court of Appeals for the Federal Circuit ("Federal Circuit"), and subsequently filed their opening brief on July 28, 2003. On September 22, 2003, we filed our responsive brief. On October 23, 2003, Plaintiffs filed their reply brief. The appeal was fully briefed and oral argument was held on March 2, 2004. The Federal Circuit on June 23, 2004 issued a ruling on the appeal in which it affirmed the District Court's claim construction ruling and summary judgment of no literal infringement by Cytogen. However, the Federal Circuit determined that there was an issue of material fact as to infringement under the doctrine of equivalents. As a result, it reversed the District Court's grant of summary judgment of no infringement under the doctrine of equivalents and remanded the case to the District Court for further proceedings on this issue. Given the uncertainty associated with litigation, we cannot give any assurance that the litigation could not result in a material adverse effect on the Company's financial condition, results of operations or liquidity.

In connection with a recent review of certain of our intellectual property, it was determined that we were the recipient, beginning in 1998, of correspondence from legal counsel representing the former employer of Dr. Julius Horoszewicz, the sole inventor on the principal United States patent covering ProstaScint. Such correspondence alleged that the patent rights to Dr. Horoszewicz's discoveries were the property of such former employer and that Dr. Horoszewicz had no right to assign them to us. We vigorously disputed those allegations, and we have no record of the matter having been pursued by such former employer subsequent to August 2000. We believe that in view of the marketing of the technology covered by the patent through the sale of ProstaScint by us, our right to use the underlying technology in our continuing production and sale of ProstaScint should not be at risk. However, if such claims were reasserted, and if it were to be concluded that Dr. Horoszewicz in fact had no right to assign the patent to us, a court could determine that we have no right to use the technology covered by the patent or that any royalties paid by or payable by us in respect of the use of the patent should have been paid in the past, and should in the future be payable, to Dr. Horoszewicz's former employer in lieu of Dr. Horoszewicz. The amount of any such payments, and our liability for them, is not presently determinable, and we cannot give any assurance that an adverse determination could not result in a material expenditure to us or have a material adverse effect on our financial condition, results of operations or liquidity.

In addition, we have certain rights to indemnification against litigation and litigation expenses from the inventor of technology used in ProstaScint, which may be offset against royalty payments on sales of

ProstaScint. However, given the uncertainty associated with litigation, we may

Edgar Filing: CYTOGEN CORP - Form 10-Q

incur material expenditures.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

CHANGES IN SECURITIES

The following information relates to all of the securities sold by us within the past quarter that were not registered under the securities laws at the time of grant, issuance and/or sale:

OPTION GRANTS

During the second quarter of 2004, we granted stock options pursuant to our 2004 Stock Incentive Plan and 2004 Non-Employee Director Stock Incentive Plan, both of which were approved by our stockholders at our Annual Meeting of Stockholders on June 15, 2004. Such options were not registered under the Securities Act of 1933, as amended, or the Securities Act. The Company intends to file a registration statement on Form S-8 with the Securities and Exchange Commission to register the shares of the Company's common stock underlying option grants or other awards under the 2004 Stock Incentive Plan and 2004 Non-Employee Director Stock Incentive Plan. All of such option grants were granted at the then current fair value of the common stock. The following table sets forth certain information regarding such grants during the quarter:

Plan ----	Number of Shares -----	Weighted Average Exercise Price Per Share -----
2004 Stock Incentive Plan.....	160,000	\$11.50
2004 Non-Employee Director Stock Incentive Plan.....	147,500	\$11.51

We did not employ an underwriter in connection with the issuance of the securities described above. We believe that the issuance of the foregoing securities was exempt from registration under either (i) Section 4(2) of the Securities Act as transactions not involving any public offering and such securities having been acquired for investment and not with a view to distribution, or (ii) Rule 701 under the Securities Act as transactions made pursuant to a written compensatory benefit plan or pursuant to a written contract relating to compensation. All recipients had adequate access to information about the Company.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

On June 15, 2004, we held our Annual Meeting of Stockholders to: (i) elect eight directors; (ii) consider and vote upon a proposal to adopt the Company's 2004 Stock Incentive Plan; (iii) consider and vote upon a proposal to adopt the Company's 2004 Non-Employee Director Stock Incentive Plan; and (iv) transact such other business as may come before the meeting.

There were represented at the our annual meeting, either in person or by proxy 13,552,506 shares of our common stock out of a total number of 15,214,249 shares of common stock issued and outstanding and entitled to vote at the meeting.

The following tables set forth information regarding the number of votes cast for, withheld, abstentions and broker non-votes, with respect to each matter presented at the meeting. Under the rules of the Nasdaq Stock Market,

Edgar Filing: CYTOGEN CORP - Form 10-Q

brokers who hold shares in street name for customers who are beneficial owners of those shares may be prohibited from giving a proxy to vote shares held for such customers on certain matters without specific instructions from such customers (broker non-votes). Under Delaware law, abstentions and broker non-votes are counted as shares represented at the meeting for purposes of determining the presence or absence of a quorum at a stockholders meeting. The election of directors is decided by a plurality of the votes cast, and therefore, votes that are withheld have no effect on the outcome of the vote. Adoption of the proposals relating to our 2004 Stock Incentive Plan and 2004 Non-Employee Director Stock Incentive Plan, required the affirmative vote of a majority of shares cast at the meeting. Therefore, abstentions and broker non-votes have no effect on the vote.

(i) Election of Directors:

NOMINEES	FOR	WITHHELD	ABSTENTIONS	BROKER NON-VOTES
James A. Grigsby	13,241,502	311,004	N/A	N/A
Michael D. Becker	13,298,108	254,398	N/A	N/A
John E. Bagalay, Jr.	11,755,093	1,797,413	N/A	N/A
Allen Bloom	13,202,905	349,601	N/A	N/A
Stephen K. Carter	13,299,637	252,869	N/A	N/A
Robert F. Hendrickson	13,209,732	342,774	N/A	N/A
Kevin G. Lokay	13,204,050	348,456	N/A	N/A
H. Joseph Reiser	13,237,927	314,579	N/A	N/A

(ii) Proposal to approve the adoption of our 2004 Stock Incentive Plan:

FOR	AGAINST	ABSTENTIONS	BROKER NON-VOTES
4,052,703	2,708,281	40,910	6,750,612

(iii) Proposal to approve the adoption of our 2004 Non-Employee Director Stock Incentive Plan:

FOR	AGAINST	ABSTENTIONS	BROKER NON-VOTES
3,896,138	2,864,779	40,977	6,750,612

ITEM 5. OTHER INFORMATION

On April 14, 2004, Thomas S. Lytle joined Cytogen as our Senior Vice President of Sales and Marketing. On June 15, 2004, we entered into a Change of Control Severance Agreement, in the form we utilize with our executive officers, with Mr. Lytle.

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.

Edgar Filing: CYTOGEN CORP - Form 10-Q

(a) Exhibits:

Exhibit No.	Description
-----	-----
10.1	Cytogen Corporation 2004 Stock Incentive Plan. Filed herewith.
10.2	Cytogen Corporation 2004 Non-Employee Director Stock Incentive Plan. Filed herewith.
31.1	Certification of President and Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Filed herewith.
31.2	Certification of Senior Vice President and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Filed herewith.
32.1	Certification of President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350. Filed herewith.
32.2	Certification of Senior Vice President and Chief Financial Officer pursuant to 18 U.S.C. Section 1350. Filed herewith.

(b) Reports on Form 8-K

On April 14, 2004, we filed a Current Report on Form 8-K disclosing correspondence related to the technology underlying our ProstaScint product.

On April 15, 2004, we filed a Current Report on Form 8-K relating to our sale and issuance of 2,570,000 shares of our common stock to certain investors.

On May 4, 2004, we furnished a Current Report on Form 8-K dated May 4, 2004, containing a copy of our earnings release for the period ended March 31, 2004 (including financial statements) pursuant to Item 12 (Results of Operations and Financial Condition).

On June 25, 2004, we filed a Current Report on Form 8-K relating to Advanced Magnetics, Inc.'s submission of a response to the approvable letter received from the United States Food and Drug Administration for Combindex.

On August 5, 2004, we furnished a Current Report on Form 8-K dated August 5, 2004, containing a copy of our earnings release for the period ended June 30, 2004 (including financial statements) pursuant to Item 12 (Results of Operations and Financial Condition).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the

Edgar Filing: CYTOGEN CORP - Form 10-Q

undersigned thereunto duly authorized.

CYTOGEN CORPORATION

Date: August 9, 2004

By: /s/ Michael D. Becker

Michael D. Becker
President and Chief Executive Officer
(Principal Executive Officer)

Date: August 9, 2004

By: /s/ Christopher P. Schnittker

Christopher P. Schnittker
Senior Vice President and
Chief Financial Officer
(Principal Financial and Accounting Officer)